Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Intangibles (2021 - 2025)

Mirum Pharmaceuticals has reported Intangibles over the past 5 years, most recently at $260.9 million for Q4 2025.

  • Quarterly results put Intangibles at $260.9 million for Q4 2025, up 4.44% from a year ago — trailing twelve months through Dec 2025 was $260.9 million (up 4.44% YoY), and the annual figure for FY2025 was $260.9 million, up 4.44%.
  • Intangibles for Q4 2025 was $260.9 million at Mirum Pharmaceuticals, up from $231.9 million in the prior quarter.
  • Over the last five years, Intangibles for MIRM hit a ceiling of $261.8 million in Q2 2024 and a floor of $18.5 million in Q1 2022.
  • Median Intangibles over the past 5 years was $234.9 million (2025), compared with a mean of $157.3 million.
  • Biggest five-year swings in Intangibles: soared 473.68% in 2023 and later fell 9.34% in 2025.
  • Mirum Pharmaceuticals' Intangibles stood at $18.7 million in 2021, then surged by 214.59% to $59.0 million in 2022, then soared by 329.02% to $252.9 million in 2023, then fell by 1.23% to $249.8 million in 2024, then grew by 4.44% to $260.9 million in 2025.
  • The last three reported values for Intangibles were $260.9 million (Q4 2025), $231.9 million (Q3 2025), and $237.9 million (Q2 2025) per Business Quant data.